[1]
K. Mystakidou, MD, PhD, E. Katsouda, MD, E. Parpa, BA, MA, M. L. Tsiatas, MD, PhD, and L. Vlahos, MD, PhD, “Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: An overview of its pharmacological and clinical characteristics”, J of Opioid Management, vol. 1, no. 1, pp. 36–40, Mar. 2005.